Future Trends in the Plasma Products Market

Latent therapeutic demand model for the immunoglobulin replacement therapy of primary immune deficiency disorders in the USA

“…The supply of IgGRT biologics has been limited because of the cost and complexity of manufacturing and the difficulty in collecting and processing the raw material – human plasma, an inherently finite resource that is needed for manufacturing . The supply‐constrained environment makes it difficult for IgGRT manufacturers to estimate future quantity demanded when deciding whether to expand production . IgGRT manufacturers need accurate demand forecasts to determine whether to expand capacity since building a new manufacturing plant is expensive.…”

“…IgGRT manufacturers need accurate demand forecasts to determine whether to expand capacity since building a new manufacturing plant is expensive. The cost for an IgGRT production facility is $100–400 million; and the timeframe to design, construct and validate the facility is 3–5 years with another 5 years to reach peak production . Treatment cost is expensive making reimbursement an issue for patients and healthcare systems .…”

Polyacrylic acid based plasma fractionation for the production of albumin and IgG: Compatibility with existing commercial downstream processes

“…Human plasma is the source of many proteins for therapeutic use. Plasma fractionation is a multibillion dollar industry which exhibits significant ongoing growth (Marcucci, 2013). This growth is mainly due to increasing demand for intravenous and subcutaneous immunoglobulin products, however, albumin demand remains strong (Goss & Curling, 2013; The Market Research Bureau, Inc., 2016).…”